A549-RFP

305659

GENERAL INFORMATION

Description

A549-RFP □□□ A549 □□ □□□□□□□□□ □□ (RFP) □□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□ A549 □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□ A549 □□□ II □□□ □□ □□□□□□□ □□□□□□□□□□□□□□□□□□ RFP □□□□□□□□□□□□□□□ □□ □□□ □□□□□□□□□□□□ □□□□□□□ A549-RFP □□ □□ A549 □□□ □□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□ □□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□ □□□□□□ A549 □□□ □□□□□□□□□□□□□□□□□□□□ □□□ □□□ E-cadherin □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ mTOR □□□□□□□□□□□□□□□□□□ RFP □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ A549 □□ □□□

A549-RFP □□ (co-culture), □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ (orthotopic) □□□□□□□□□□□□□□□□□□□□□□□□ (ectopic), □□□□□□□□□□□□□□□□□□□□□□ □□□ □□□ □□□ □□□□□□□□□ □□□ □ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□ (high-content screening) □□□ (flow cytometry) □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□ (in vivo optical imaging) □□□ □□ A549-RFP □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□ □□ □□□□□□□□□□ (epithelial-mesenchymal transition) □□□□□□□□□□□□□□□□□□□□□□ □□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□ in vitro □□□ in vivo

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□: □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ (RFP) □□□□□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□□□□ □□ (1–5 µg/mL). □□□□□□□□□□□□□□□□□□□□□□□ S1/BSL-1

Tissue	□□□
Disease	□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

Synonyms

- A 549
- A549
- NCI-A549
- A549/ATCC
- A549 ATCC
- A549ATCC
- hA549

CLASSIFICATION

Organism	Human
Sex	Male
Growth properties	Adherent
GMO status	GMO-S1

GMO status details

GMO-S1: This cell line contains a stably integrated red fluorescent protein (RFP) reporter introduced via replication-incompetent lentiviral transduction. The resulting polyclonal cell population was maintained under puromycin selection (1–5 µg/mL). S1 containment is required. This classification applies only within Germany and may differ elsewhere.

Biosafety level	1

CHARACTERISTICS

Doubling time	20-40 □□□□□□□□

IDENTIFIERS

Citation

A549-RFP (□□□□□□□□□□□□□□□□□□ Cytion 305659)

NCBI TaxID	9606
Cellosaurus	CVCL_0023

EXPRESSION AND SUSCEPTIBILITY

Antigen expression

□□□□□□□□□□ (□□□□□□□□□□□□□□□□□□□□□□)

Mutational profile

□□□□□□□□□□□□□□□: p.Gly12Ser, □□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□: p.Gln37Ter, □□□□□□□□□□□□□□□

HANDLING AND CULTURE

Culture medium

DMEM:Ham's F12 (1:1), w: 3.1 □□□□/□□□□ □□□□□□, w: 2.5 □□□□□□□□□□□□ L-□□□□□□□□, w: 15 □□□□□□□□□□□□ HEPES, w: 0.5 □□□□□□□□□□□□ □□□□□□□□□□□□□□□□, w: 1.2 □□□□/□□□□ NaHCO3 (□□□□□□ Cytion □□□□□□□□ 820400a

Incubation atmosphere	37°C, 5%CO2, □□□□□□□□□□□□□□

Supplements

□□□□□□□□□□□□□□□□□□□□□□□□□□□□ FBS 10%

Dissociation reagent	□□□□□□□□□

Thawing and culturing

Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.
Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.
For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.
Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.
Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.
Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.
Follow the procedure described under Post-Thaw Recovery

QUALITY CONTROL AND CRYOPRESERVATION

Freeze medium	□□□ □□□□□□□□□□□□□□□□□□□□ □□□ + 10% DMSO □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

Storage conditions

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□ −150 □□□ −196 °C □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ −80 °C □□ □□□□□□□□□□□□□□□□□□□□□□□□

Shipping conditions

□□ □□ □□□□□□□ −78 °C □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□ □□ □□□

DONOR

Donor age	58 □□
Ethnicity	□□□□□□□□□□

LEGAL AND SAFETY

Safety precautions

□□ □□ □□□ □□ □□□ □□□□□□□□□□□□□□□□□□□□□ □□□

Warranty

□□□Cytion □□
□□
60 □□□
□□□
□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□/□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□
<a href=""/Who-we-are/Warranty/"" hreflang=""x-default"">□□□□□□□□□□□□□□□□□□□□□□□□□□□.

Material Transfer Agreement required	Yes

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB